ArticleBMC infectious diseases2013
Multiple-antigen ELISA for melioidosis--a novel approach to the improved serodiagnosis of melioidosis.
Article in BMC infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Antibodies toMicroorganisms · 2026Article
- Laboratory diagnosis of melioidosis.PLoS neglected tropical diseases · 2025Review
- Stability assessment of whole cell ELISA for Burkholderia pseudomallei antibodies detection.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Comparison of immunogenicity of 17 Burkholderia mallei antigens and whole cell lysate using indirect ELISA.The Journal of veterinary medical science · 2025Article
- Detection and analysis of Serpin and RP26 specific antibodies for monitoring Schistosoma haematobium transmission.PLoS neglected tropical diseases · 2025Article
- Performance of Antibody-Detection Tests for Human Melioidosis: A Systematic Review and Meta-analysis.The Malaysian journal of medical sciences : MJMS · 2024Review
- Review
- MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection.Pathogens (Basel, Switzerland) · 2023Article
- Enhanced serodiagnosis of melioidosis by indirect ELISA using the chimeric protein rGroEL-FLAG300 as an antigen.BMC infectious diseases · 2022Article
- multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection.medRxiv : the preprint server for health sciences · 2021Article
- Use of RecombinantPathogens (Basel, Switzerland) · 2021Article
- Septicemic Melioidosis Detection Using Support Vector Machine with Five Immune Cell Types.Disease markers · 2021Article
- Distribution of Serological Response toInternational journal of environmental research and public health · 2020Article
- Adapting Microarray Gene Expression Signatures for Early Melioidosis Diagnosis.Journal of clinical microbiology · 2020Article
- Antibodies in Melioidosis: The Role of the Indirect Hemagglutination Assay in Evaluating Patients and Exposed Populations.The American journal of tropical medicine and hygiene · 2018Article
- Comparison of in-house IgM and IgG ELISAs for the serodiagnosis of melioidosis in Malaysia.Journal of medical microbiology · 2017Article
- Evolving serodiagnostics by rationally designed peptide arrays: the Burkholderia paradigm in Cystic Fibrosis.Scientific reports · 2016Article
- Efficacy of indirect ELISA for serodiagnosis of melioidosis using immunodominant antigens from non-pathogenicSpringerPlus · 2016Article
- Development of repeatable arrays of proteins using immobilized DNA microplate (RAPID-M) technology.BMC research notes · 2015Article
- Laboratory diagnosis of melioidosis: past, present and future.Experimental biology and medicine (Maywood, N.J.) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBurkholderia pseudomallei, the causative agent of melioidosis, is endemic to Southeast Asia and northern Australia. Clinical manifestations of disease are diverse, ranging from chronic infection to acute septicaemia. The current gold standard of diagnosis involves bacterial culture and identification which is time consuming and often too late for early medical intervention. Hence, rapid diagnosis of melioidosis is crucial for the successful management of melioidosis.
methodsThe study evaluated 4 purified B. pseudomallei recombinant proteins (TssD-5, Omp3, smBpF4 and Omp85) as potential diagnostic agents for melioidosis. A total of 68 sera samples from Malaysian melioidosis patients were screened for the presence of specific antibodies towards these proteins using enzyme-linked immunosorbent assay (ELISA). Sera from patients with various bacterial and viral infections but negative for B. pseudomallei, as well as sera from healthy individuals, were also included as non-melioidosis controls. The Mann Whitney test was performed to compare the statistical differences between melioidosis patients and the non-melioidosis controls.
resultsTssD-5 demonstrated the highest sensitivity of 71% followed by Omp3 (59%), smBpF4 (41%) and Omp85 (19%). All 4 antigens showed equally high specificity (89-96%). A cocktail of all 4 antigens resulted in slightly reduced sensitivity of 65% but improved specificity (99%). Multiple-antigen ELISA provided improved sensitivity of 88.2% whilst retaining good specificity (96%). There was minimal reactivity with sera from healthy individuals proposing the utility of these antigens to demarcate diseased from non-symptomatic individuals in an endemic country.
conclusionsTssD-5 demonstrated high detection sensitivity and specificity and the results were obtained within a few hours compared to time consuming culture and IFAT methods commonly used in a clinical setting. The use of multiple-antigens resulted in improved sensitivity (88.2%) whilst maintaining superior specificity. These data highlight the use of TssD-5 and other recombinant antigens tested in this study as potential serodiagnostic agents for melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.